McCloskey, Eugene V <br/><br/>
Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.  [electronic resource] 

 -  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research  Jul 2012 
 - 1480-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1523-4681 
<br/><br/><label>Standard No.: </label>10.1002/jbmr.1606  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Algorithms<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Body Mass Index<br/>Bone Density Conservation Agents--therapeutic use<br/>Denosumab<br/>Female<br/>Fracture Healing<br/>Humans<br/>Middle Aged<br/>Osteoporosis--drug therapy<br/>Osteoporotic Fractures--prevention & control<br/>Placebos<br/>Postmenopause<br/>Probability<br/>Proportional Hazards Models<br/>Risk<br/>Risk Assessment